Please confirm you are human (Sign Up for free to never see this)
← Back to Search
Immune Checkpoint Blockade In Cancer Therapy.
M. Postow, M. Callahan, J. Wolchok
Published 2015 · Medicine
Save to my Library
Download PDFAnalyze on Scholarcy
Immunologic checkpoint blockade with antibodies that target cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and the programmed cell death protein 1 pathway (PD-1/PD-L1) have demonstrated promise in a variety of malignancies. Ipilimumab (CTLA-4) and pembrolizumab (PD-1) are approved by the US Food and Drug Administration for the treatment of advanced melanoma, and additional regulatory approvals are expected across the oncologic spectrum for a variety of other agents that target these pathways. Treatment with both CTLA-4 and PD-1/PD-L1 blockade is associated with a unique pattern of adverse events called immune-related adverse events, and occasionally, unusual kinetics of tumor response are seen. Combination approaches involving CTLA-4 and PD-1/PD-L1 blockade are being investigated to determine whether they enhance the efficacy of either approach alone. Principles learned during the development of CTLA-4 and PD-1/PD-L1 approaches will likely be used as new immunologic checkpoint blocking antibodies begin clinical investigation.
This paper references
Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients
F. S. Hodi (2008)
Opportunistic infections in patients treated with immunotherapy for cancer
Chrisann Kyi (2014)
Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation
G. Freeman (2000)
Tissue expression of PD-L1 mediates peripheral T cell tolerance
M. Keir (2006)
Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma
G. Phan (2003)
Reversal of the TCR Stop Signal by CTLA-4
H. Schneider (2006)
Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC).
A. Amin (2014)
Kidney injuries related to ipilimumab
H. Izzedine (2014)
bined BRAF and MEK inhibition in melanoma with BRAF V 600 mutations
KT Flaherty (2012)
Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer.
S. Demaria (2005)
Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma.
D. Schadendorf (2015)
Combination Immunotherapy of B16 Melanoma Using Anti–Cytotoxic T Lymphocyte–Associated Antigen 4 (Ctla-4) and Granulocyte/Macrophage Colony-Stimulating Factor (Gm-Csf)-Producing Vaccines Induces Rejection of Subcutaneous and Metastatic Tumors Accompanied by Autoimmune Depigmentation
A. van Elsas (1999)
Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
J. Wolchok (2009)
Improved survival with ipilimumab in patients with metastatic melanoma.
F. S. Hodi (2010)
Ipilimumab in patients with cancer and the management of dermatologic adverse events.
M. Lacouture (2014)
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
C. Robert (2014)
Exome sequencing reveals a genetic basis underlying clinical response to CTLA-4 blockade
A Snyder (2014)
Efficacy and Safety of Retreatment with Ipilimumab in Patients with Pretreated Advanced Melanoma Who Progressed after Initially Achieving Disease Control
C. Robert (2013)
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations.
K. Flaherty (2012)
A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma
O. Hamid (2010)
Management of immune-related adverse events and kinetics of response with ipilimumab.
J. Weber (2012)
Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial.
E. Kwon (2014)
CTLA-4 is a second receptor for the B cell activation antigen B7
P. Linsley (1991)
Nivolumab plus ipilimumab in advanced melanoma.
J. Wolchok (2013)
Inhibition of PD-L1 by MPDL3280A and clinical activity in pts with metastatic urothelial bladder cancer (UBC).
T. Powles (2014)
Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma
A. Parsa (2007)
Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti–PD-1 Therapy
J. Taube (2014)
New monoclonal antibodies against B-cell antigens: possible new strategies for diagnosis of primary cutaneous B-cell lymphomas.
D. Fanoni (2011)
Patterns of onset and resolution of immune‐related adverse events of special interest with ipilimumab
J. Weber (2013)
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
S. Topalian (2012)
Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial.
L. Calabrò (2013)
Randomized phase I pharmacokinetic study of ipilimumab with or without one of two different chemotherapy regimens in patients with untreated advanced melanoma.
J. Weber (2013)
Phase I Safety and Pharmacokinetic Study of CT-011, a Humanized Antibody Interacting with PD-1, in Patients with Advanced Hematologic Malignancies
R. Berger (2008)
Severe relapse in a multiple sclerosis patient associated with ipilimumab treatment of melanoma
E. Gettings (2015)
Improved Endpoints for Cancer Immunotherapy Trials
A. Hoos (2010)
Infliximab in the treatment of anti-CTLA4 antibody (ipilimumab) induced immune-related colitis.
D. Minor (2009)
Evaluation of immune-related response criteria (irRC) in patients (pts) with advanced melanoma (MEL) treated with the anti-PD-1 monoclonal antibody MK-3475.
F. S. Hodi (2014)
Preliminary data from a multi-arm expansion study of MEDI4736, an anti-PD-L1 antibody.
N. Segal (2014)
Preliminary results from a phase 1/2 study of INCB024360 combined with ipilimumab (ipi) in patients (pts) with melanoma.
Geoffrey T. Gibney (2014)
Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma.
Nienke van Rooij (2013)
Induced expression of PD‐1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death.
Y. Ishida (1992)
Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma
E. Simeone (2014)
Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4.
E. Tivol (1995)
Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases
A. D. Giacomo (2008)
Immune-mediated red cell aplasia after anti-CTLA-4 immunotherapy for metastatic melanoma
Ilyssa O. Gordon (2008)
Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4
P. Waterhouse (1995)
Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma.
J. Weber (2013)
Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial.
J. Westin (2014)
Immune parameters affecting the efficacy of chemotherapeutic regimens
L. Zitvogel (2011)
Neutropenia in a patient treated with ipilimumab (anti-CTLA-4 antibody).
M. Akhtari (2009)
Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes
T. Dillard (2009)
AntiCTLA-4 antibody therapy associated autoimmune hypophysitis: Serious immune related adverse events across a spectrum of cancer
T Dillard (2010)
Imaging of CTLA4 Blockade–Induced Cell Replication with 18F-FLT PET in Patients with Advanced Melanoma Treated with Tremelimumab
A. Ribas (2010)
Combining radiotherapy and cancer immunotherapy: a paradigm shift.
S. Formenti (2013)
Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab
J. Yuan (2011)
Anti-CTLA-4 antibody-induced Guillain-Barré syndrome in a melanoma patient.
S. Wilgenhof (2011)
Increased Frequency of ICOS+ CD4 T Cells as a Pharmacodynamic Biomarker for Anti-CTLA-4 Therapy
D. Ng Tang (2013)
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
H. Dong (2002)
Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer.
J. Blansfield (2005)
Genetic basis for clinical response to CTLA-4 blockade in melanoma.
A. Snyder (2014)
Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival.
J. Delyon (2013)
Immunologic correlates of the abscopal effect in a patient with melanoma.
M. Postow (2012)
Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor.
H. Nishimura (1999)
Durable Cancer Regression Off-Treatment and Effective Reinduction Therapy with an Anti-PD-1 Antibody
E. Lipson (2012)
Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice.
H. Nishimura (2001)
Effects of MAPK and PI3K Pathways on PD-L1 Expression in Melanoma
Mohammad S Atefi (2014)
olumab ( anti - PD - 1 ; BMS - 936558 , ONO - 4538 ) in combination with sunitinib or pazopanib in patients ( pts ) with metastatic renal cell carcinoma ( mRCC )
SC Formenti (2014)
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.
J. Brahmer (2012)
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.
C. Robert (2011)
Hepatotoxicity with combination of vemurafenib and ipilimumab.
A. Ribas (2013)
Concurrent Radiotherapy and Ipilimumab Immunotherapy for Patients with Melanoma
C. Barker (2013)
Ipilimumab-induced acute severe colitis treated by infliximab.
C. Pages (2013)
An Abscopal Response to Radiation and Ipilimumab in a Patient with Metastatic Non–Small Cell Lung Cancer
E. Golden (2013)
An immune-active tumor microenvironment favors clinical response to ipilimumab
R. Ji (2011)
Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma.
A. Ribas (2013)
Modulation of TCR-induced transcriptional profiles by ligation of CD28, ICOS, and CTLA-4 receptors
J. Riley (2002)
Successful treatment with Ipilimumab and Interleukin-2 in two patients with metastatic melanoma and systemic autoimmune disease
Magnus Pedersen (2014)
Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206.
A. Ribas (2005)
Yervoy ( ipilimumab ) : Immune - mediated adverse reaction management guide
CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells
M. Krummel (1996)
Phase 1 dose‐escalation trial of tremelimumab plus sunitinib in patients with metastatic renal cell carcinoma
B. Rini (2011)
Ryan J. Sullivan (2013)
Combining targeted therapy with immunotherapy in BRAF-mutant melanoma: promise and challenges.
S. Hu-Lieskovan (2014)
Cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma: a new cause of uveitis.
M. Robinson (2004)
Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.
O. Hamid (2013)
1085OSURVIVAL, RESPONSE DURATION, AND ACTIVITY BY BRAF MUTATION (MT) STATUS IN A PHASE 1 TRIAL OF NIVOLUMAB (ANTI-PD-1, BMS-936558, ONO-4538) AND IPILIMUMAB (IPI) CONCURRENT THERAPY IN ADVANCED MELANOMA (MEL).
H. Kluger (2014)
Developing a Common Language for Tumor Response to Immunotherapy: Immune-Related Response Criteria Using Unidimensional Measurements
M. Nishino (2013)
Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL).
H. Kluger (2014)
Trans-Endocytosis of CD80 and CD86: A Molecular Basis for the Cell-Extrinsic Function of CTLA-4
O. Qureshi (2011)
Biomarkers on melanoma patient T Cells associated with ipilimumab treatment
W. Wang (2012)
Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study.
S. Slovin (2013)
Phase I open-label, multiple ascending dose trial of MSB0010718C, an anti-PD-L1 monoclonal antibody, in advanced solid malignancies.
C. Heery (2014)
Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials.
J. Wolchok (2013)
Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study.
T. Lynch (2012)
Enhancement of Antitumor Immunity by CTLA-4 Blockade
D. Leach (1996)
Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab.
S. Topalian (2014)
LBA3_PRA PHASE 3 RANDOMIZED, OPEN-LABEL STUDY OF NIVOLUMAB (ANTI-PD-1; BMS-936558; ONO-4538) VERSUS INVESTIGATOR'S CHOICE CHEMOTHERAPY (ICC) IN PATIENTS WITH ADVANCED MELANOMA AFTER PRIOR ANTI-CTLA-4 THERAPY
J. Weber (2014)
hancement of antitumor immunity by CTLA - 4 block
A vanElsas (1996)
Case records of the Massachusetts General Hospital. Case 21-2013. A 68-year-old man with metastatic melanoma.
R. Sullivan (2013)
Multicenter, randomized phase II trial of GM-CSF (GM) plus ipilimumab (Ipi) versus Ipi alone in metastatic melanoma: E1608.
S. Lee (2013)
Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice.
L. Deng (2014)
CTLA-4 Blockade with Ipilimumab: Long-term Follow-up of 177 Patients with Metastatic Melanoma
P. A. Prieto (2012)
Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non--small-cell lung cancer: a Southwest Oncology Group trial.
K. Kelly (2001)
Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial.
P. Armand (2013)
Association of tumor PD-L1 expression and immune biomarkers with clinical activity in patients (pts) with advanced solid tumors treated with nivolumab (anti-PD-1; BMS-936558; ONO-4538).
Joseph F. Grosso (2013)
Phase 1 study of the BRAF inhibitor dabrafenib (D) with or without the MEK inhibitor trametinib (T) in combination with ipilimumab (Ipi) for V600E/K mutation–positive unresectable or metastatic melanoma (MM).
I. Puzanov (2014)
Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy
A. Grimaldi (2014)
Ipilimumab in patients with melanoma and autoimmune disease
Chrisann Kyi (2014)
Evaluation of Ipilimumab in Combination With Allogeneic Pancreatic Tumor Cells Transfected With a GM-CSF Gene in Previously Treated Pancreatic Cancer
D. Le (2013)
Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses.
M. Butte (2007)
Preoperative CTLA-4 Blockade: Tolerability and Immune Monitoring in the Setting of a Presurgical Clinical Trial
B. Carthon (2010)
The heterogeneity of the kinetics of response to ipilimumab in metastatic melanoma: patient cases.
Y. Saenger (2008)
Primary analysis of a phase 1b multicenter trial to evaluate safety and efficacy of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) in previously untreated, unresected stage IIIB-IV melanoma.
I. Puzanov (2014)
Clinical and pharmacodynamic (PD) results of a phase I trial with AMP-224 (B7-DC Fc) that binds to the PD-1 receptor.
J. Infante (2013)
A study of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic tumors.
R. Herbst (2013)
Pharmacodynamic effect of ipilimumab on absolute lymphocyte count (ALC) and association with overall survival in patients with advanced melanoma.
M. Postow (2013)
This paper is referenced by
Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of ASP2408, a Potent Selective T‐Cell Costimulation Modulator After Single and Multiple Ascending Doses in Healthy Volunteers and RA Patients
Tong Zhu (2016)
Oxaliplatin induces immunogenic cells death and enhances therapeutic efficacy of checkpoint inhibitor in a model of murine lung carcinoma
Fengfei Sun (2019)
Targeting Interleukin-6 (IL-6) Sensitizes Anti-PD-L1 Treatment in a Colorectal Cancer Preclinical Model
Jibin Li (2018)
Immunotherapy for Treatment of Cancer
Aida Karachi (2018)
A randomized phase II trial of personalized peptide vaccine with low dose cyclophosphamide in biliary tract cancer
Takahisa Shirahama (2017)
The efficacy and safety of immune checkpoint inhibitors in non-small cell lung cancer patients of different age groups: a meta-analysis
S.-Y. Zheng (2019)
Clinical spectrum of neuromuscular complications after immune checkpoint inhibition
A. Puwanant (2019)
Prognostic value of programmed cell death ligand 1 (PD-L1) for hepatocellular carcinoma: a meta-analysis
X. Li (2020)
Combining PARP Inhibition, Radiation, and Immunotherapy: A Possible Strategy to Improve the Treatment of Cancer?
Mathieu Césaire (2018)
Immune check-point in glioblastoma multiforme.
F. De Felice (2019)
Prognostic and Predictive Immunohistochemistry-Based Biomarkers in Cancer and Immunotherapy.
Emanuelle M. Rizk (2019)
T Cell Calcium Signaling Regulation by the Co-Receptor CD5
C. M. T. Freitas (2018)
Prognostic Factors for Checkpoint Inhibitor Based Immunotherapy: An Update With New Evidences
Xinyu Yan (2018)
Chimeric antigen receptor transduced T cells: Tuning up for the next generation
M. Schubert (2018)
The prospects and promise of chimeric antigen receptor immunotherapy in multiple myeloma
A. Rotolo (2016)
Evolution of checkpoint inhibitors for the treatment of metastatic gastric cancers: Current status and future perspectives.
J. Taieb (2018)
Antibody-drug conjugates: Current status and future perspectives.
Rémy Gébleux (2016)
S. Zhao (2019)
TFEB Mediates Immune Evasion and Resistance to mTOR Inhibition of Renal Cell Carcinoma via Induction of PD-L1
Cai Zhang (2019)
Immune Checkpoint inhibitors: An introduction to the next‐generation cancer immunotherapy
Lucy Lee (2016)
Programmed death 1 blockade, an Achilles heel for MMR-deficient tumors?
A. Lin (2015)
Sunitinib and Sorafenib Modulating Antitumor Immunity in Hepatocellular Cancer
Dai Liu (2018)
Cancer immunotherapy: the art of targeting the tumor immune microenvironment
J. L. da Silva (2019)
Avelumab, an Anti–Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study
A. Apolo (2017)
Promising investigational drug candidates in phase I and phase II clinical trials for mesothelioma
A. Guazzelli (2017)
A simple open-source method for highly multiplexed imaging of single cells in tissues and tumours
Jia-Ren Lin (2017)
Divergent Resistance Mechanisms to Immunotherapy Explain Responses in Different Skin Cancers
Emmanuel Dollinger (2020)
Bidirectional Crosstalk Between Cancer Stem Cells and Immune Cell Subsets
Luise Müller (2020)
A Comprehensive Analysis of Programmed Cell Death Ligand-1 Expression With the Clone SP142 Antibody in Non-Small-Cell Lung Cancer Patients.
K. Takada (2017)
p110δ PI3K as a therapeutic target of solid tumours.
Lydia Xenou (2020)
Overview of Current Immunotherapies Targeting Mutated KRAS Cancers.
W. Hoo (2019)
Upregulation of Cytotoxic T-Lymphocyte- Associated Protein 4 and Forkhead Box P3 Transcripts in Peripheral Blood of Patients with Bladder Cancer
Ali Ariafar (2021)See more